L9 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2005:1154407 CAPLUS Full-text
DN 143:427370
TI Maytansinoid analogs as antitumor agents
IN Cassady, John M.; Floss, Heinz G.
PA The Ohio State University Research Foundation, USA
SO PCT Int. Appl., 18 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005099754	A2	20051027	WO 2005-US11441	20050404
	WO 2005099754	A3	20060309		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 20080249085	A1	20081009	US 2008-599930	20080425
PRAI	US 2004-562119P	P	20040414		
	WO 2005-US11441	W	20050404		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS MARPAT 143:427370
AB Ansamycin analogs, including maytansinoid analogs, and their use in treating cell proliferative diseases and conditions, and in particular, for use as antitumor agents are disclosed.
IT 868076-22-6P 868076-23-7P
RL: BPN (Biosynthetic preparation); PNU (Preparation, unclassified); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(maytansinoid analogs as antitumor agents)
RN 868076-22-6 CAPLUS
CN Maytansine, 2'-de(acetylmethylamino)-20-demethoxy-18,20-dihydro-2'-methyl-18,20-dioxo- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 868076-23-7 CAPLUS
CN Maytansine, 2'-de(acetylmethylamino)-20-demethoxy-21-[[2-(dimethylamino)ethyl]amino]-17,20-dihydro-2'-methyl-17,20-dioxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1984:121094 CAPLUS Full-text
DN 100:121094
OREF 100:18433a,18436a
TI Maytansinoid compounds
PA Takeda Chemical Industries, Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 10 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 58167592	A	19831003	JP 1982-49836	19820326
	JP 01052397	B	19891108		
PRAI	JP 1982-49836		19820326		

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Twenty-three maytansinoid compds. I [R = alkyl; X = Q, Q1, Q2, Q3 (R1, R2 = H, alkyl; R1R2 may be CH2)] were prepared by oxidation of II optionally followed by reduction and alkylation. I had mitosis inhibitory, anticarcinogenic, antifungal, and anti-protozoa activities (no data). Thus, treatment of 1.24 g II (R = Me2CH) in MeOH containing KH2PO4 with 250 mL Flemy's salt-saturated H2O for 3 h followed by SiO2 gel thin layer chromatog. of the product (22 mg) gave 18 mg I (R = Me2CH, X = Q) and I (R = Me2CH, X = Q1).

IT 89153-72-0P 89153-73-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 89153-72-0 CAPLUS
CN Maytansine, 2'-de(acetylmethylamino)-20-demethoxy-17,20-dihydro-17,20-dioxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 89153-73-1 CAPLUS

CN Maytansine, 3-O-de[2-(acetylmethylamino)-1-oxopropyl]-20-demethoxy-17,20-dihydro-3-O-(3-methyl-1-oxobutyl)-17,20-dioxo- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L14 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2005:1154407 CAPLUS Full-text
DN 143:427370
TI Maytansinoid analogs as antitumor agents
IN Cassady, John M.; Floss, Heinz G.
PA The Ohio State University Research Foundation, USA
SO PCT Int. Appl., 18 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005099754	A2	20051027	WO 2005-US11441	20050404
	WO 2005099754	A3	20060309		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 20080249085	A1	20081009	US 2008-599930	20080425
PRAI	US 2004-562119P	P	20040414		
	WO 2005-US11441	W	20050404		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS MARPAT 143:427370
AB Ansamycin analogs, including maytansinoid analogs, and their use in treating cell proliferative diseases and conditions, and in particular, for use as antitumor agents are disclosed.
IT 868076-22-6P 868076-23-7P 868076-24-8P
868076-25-9P
RL: BPN (Biosynthetic preparation); PNU (Preparation, unclassified); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(maytansinoid analogs as antitumor agents)
RN 868076-22-6 CAPLUS
CN Maytansine, 2'-de(acetylmethylamino)-20-demethoxy-18,20-dihydro-2'-methyl-18,20-dioxo- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 868076-23-7 CAPLUS
CN Maytansine, 2'-de(acetylmethylamino)-20-demethoxy-21-[[2-(dimethylamino)ethyl]amino]-17,20-dihydro-2'-methyl-17,20-dioxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 868076-24-8 CAPLUS
CN Maytansine, 2'-de(acetylmethylamino)-19-dechloro-4,5-deepoxy-4,5-didehydro-20-demethoxy-22-demethyl-21-[[2-(dimethylamino)ethyl]amino]-17,20-dihydro-2'-methyl-17,20-dioxo-, (4E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 868076-25-9 CAPLUS
CN Maytansine, 2'-de(acetylmethylamino)-19-dechloro-4,5-deepoxy-4,5-didehydro-20-demethoxy-22-demethyl-17,20-dihydro-2'-methyl-17,20-dioxo-, (4E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1984:121094 CAPLUS Full-text
DN 100:121094
OREF 100:18433a,18436a
TI Maytansinoid compounds
PA Takeda Chemical Industries, Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 10 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 58167592	A	19831003	JP 1982-49836	19820326
	JP 01052397	B	19891108		
PRAI	JP 1982-49836		19820326		

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Twenty-three maytansinoid compds. I [R = alkyl; X = Q, Q1, Q2, Q3 (R1, R2 = H, alkyl; R1R2 may be CH2)] were prepared by oxidation of II optionally followed by reduction and alkylation. I had mitosis inhibitory, anticarcinogenic, antifungal, and anti-protozoa activities (no data). Thus, treatment of 1.24 g II (R = Me2CH) in MeOH containing KH2PO4 with 250 mL Flemy's salt-saturated H2O for 3 h followed by SiO2 gel thin layer chromatog. of the product (22 mg) gave 18 mg I (R = Me2CH, X = Q) and I (R = Me2CH, X = Q1).

IT 89153-72-0P 89153-73-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 89153-72-0 CAPLUS
CN Maytansine, 2'-de(acetylmethylamino)-20-demethoxy-17,20-dihydro-17,20-dioxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 89153-73-1 CAPLUS

CN Maytansine, 3-O-de[2-(acetylmethylamino)-1-oxopropyl]-20-demethoxy-17,20-dihydro-3-O-(3-methyl-1-oxobutyl)-17,20-dioxo- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L19 ANSWER 1 OF 18 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2009:1266638 CAPLUS Full-text
DN 151:446290
TI Novel ansamitocin derivatives
IN Sasse, Florenz; Kirschning, Andreas; Grond, Stephanie
PA Leibniz Universitat Hannover, Germany; Helmholtz-Zentrum fuer Infektionsforschung GmbH; Georg-August-Universitat Goettingen
SO U.S. Pat. Appl. Publ., 16pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 20090258870	A1	20091015	US 2009-408568	20090320
PRAI US 2008-70120P	P	20080320		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS CASREACT 151:446290; MARPAT 151:446290
AB Provided are among other things ansamitocin derivs., pharmaceutical compns. comprising these novel ansamitocin derivs., methods for the production of the ansamitocin derivs. and their use for the treatment of cancer.
IT 1187832-14-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(novel ansamitocin derivs.)
RN 1187832-14-9 CAPLUS
CN Maytansine, 2'-de(acetylmethylamino)-19-dechloro-19-hydroxy-2'-methyl- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L19 ANSWER 2 OF 18 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2009:1155108 CAPLUS Full-text
DN 151:381095
TI Preparation of ansamitocin derivatives as antitumor agents
IN Sasse, Florenz; Kirschning, Andreas; Grond, Stephanie
PA Leibniz Universitaet Hannover, Germany; Helmholtz-Zentrum fuer Infektionsforschung GmbH; Georg-August-Universitaet Goettingen
SO Eur. Pat. Appl., 27pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 2103618	A1	20090923	EP 2008-5327	20080320
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, AL, BA, MK, RS				
PRAI EP 2008-5327		20080320		

OS MARPAT 151:381095
GI



I



II

AB Ansamitocin derivs. of formula I [R1 = H, halo, alkyl, cycloalkyl, etc.; R2 = H, halo, OH, NH2, SH, alkyl, etc.; R1R2 = (hetero)alkylene, etc.; R3 = H, F; R4 = H, Me; A = bond, O; Y = Me, iso-Pr, isobutyl] are prepared, by fermentation or chemical methods, for the treatment of cancer. Thus, II was prepared, and had IC50 = 0.18 ng/mL against KB-3-1 cervix carcinoma cell line.

IT 1187832-14-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of ansamitocin derivs. as antitumor agents)

RN 1187832-14-9 CAPLUS
CN Maytansine, 2'-de(acetylmethylamino)-19-dechloro-19-hydroxy-2'-methyl- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 3 OF 18 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2005:1154407 CAPLUS Full-text
DN 143:427370
TI Maytansinoid analogs as antitumor agents
IN Cassady, John M.; Floss, Heinz G.
PA The Ohio State University Research Foundation, USA
SO PCT Int. Appl., 18 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005099754	A2	20051027	WO 2005-US11441	20050404
	WO 2005099754	A3	20060309		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 20080249085	A1	20081009	US 2008-599930	20080425
PRAI	US 2004-562119P	P	20040414		
	WO 2005-US11441	W	20050404		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS MARPAT 143:427370
AB Ansamycin analogs, including maytansinoid analogs, and their use in treating cell proliferative diseases and conditions, and in particular, for use as antitumor agents are disclosed.
IT 868076-26-0P
RL: BPN (Biosynthetic preparation); PNU (Preparation, unclassified); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(maytansinoid analogs as antitumor agents)
RN 868076-26-0 CAPLUS
CN Propanoic acid, 2-methyl-, (7R,8S,12S,13S,16S)-8,22-dihydroxy-7-methoxy-3,13,15-trimethyl-10,18-dioxo-11-oxa-9,19-diazatricyclo[18.3.1.18,12]pentacosa-1(24),3,5,14,20,22-hexaen-16-yl ester (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2005:273106 CAPLUS Full-text
DN 142:475230
TI Metabolism studies of the anti-tumor agent maytansine and its analog ansamitocin P-3 using liquid chromatography/tandem mass spectrometry
AU Liu, Zhongfa; Floss, Heinz G.; Cassady, John M.; Chan, Kenneth K.
CS College of Pharmacy, Ohio State University, Columbus, OH, 43210, USA
SO Journal of Mass Spectrometry (2005), 40(3), 389-399
CODEN: JMSPFJ; ISSN: 1076-5174
PB John Wiley & Sons Ltd.
DT Journal
LA English
AB Maytansine, a potent clin. evaluated plant-derived antitumor drug, and its microbial counterpart, ansamitocin P-3, showed a substantially higher cytotoxicity than many other antitumor drugs. Owing to a shortage of material and lack of sufficiently sensitive anal. methods at the time, no metabolism studies were apparently carried out in conjunction with the initial preclin. and clin. studies on maytansine, but some products of decomposition during the period of storage of the formulated drug were reported. In the current study, the in vitro metabolism of maytansine and ansamitocin P-3 was studied after incubation with rat and human liver microsomes in the presence of NADPH, and with rat and human plasma and whole blood, using liquid chromatog./multi-stage mass spectrometry. Unchanged ansamitocin P-3 and 11 metabolites and unchanged maytansine and seven metabolites were profiled and the structures of some metabolites were tentatively assigned based on their multi-stage electrospray ion-trap mass fragmentation data and in some cases accurate mass measurement. The major pathway of ansamitocin P-3 metabolism in human liver microsomes appears to be demethylation at C-10. Oxidation and sequential oxidation/demethylation also occurred, although to a lesser extent. However, the major pathway of maytansine metabolism in human liver microsomes is N-demethylation of the methylamide of the ester moiety. Several minor pathways including O/N-demethylation, oxidation and hydrolysis of the ester bond were also observed There were no differences in maytansine metabolism between rat and human liver microsomes; however, the rate of metabolism of ansamitocin P-3 was different in rat and human liver microsomes. About 20% of ansamitocin P-3 was converted to its metabolites in rat liver microsomes and about 70% in human liver microsomes under the same conditions. Addnl., 10-O-demethylated ansamitocin P-3 was also detected in the urine after i.v. bolus administration of ansamitocin P-3 to Sprague-Dawley male rats. No metabolites were detected following incubation of maytansine and ansamitocin P-3 with human and rat whole blood and plasma.
IT 72902-38-6 851860-10-1 851860-11-2
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(metabolism studies of antitumor agent maytansine and its analog ansamitocin P-3 using liquid chromatog./tandem mass spectrometry)
RN 72902-38-6 CAPLUS
CN Maytansine, 2'-de(acetylmethylamino)-O20-demethyl-2'-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 851860-10-1 CAPLUS
CN Maytansine, 2'-de(acetylmethylamino)-20-O-demethyl-15-hydroxy-2'-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 851860-11-2 CAPLUS
CN Maytansine, 2'-de(acetylmethylamino)-20-O-demethyl-30-hydroxy-2'-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



OSC.G 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD (8 CITINGS)
RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 5 OF 18 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2003:860618 CAPLUS Full-text
DN 140:73150
TI The Post-Polyketide Synthase Modification Steps in the Biosynthesis of the Antitumor Agent Ansamitocin by Actinosynnema pretiosum
AU Spiteller, Peter; Bai, Linquan; Shang, Guangdong; Carroll, Brian J.; Yu, Tin-Wein; Floss, Heinz G.
CS Department of Chemistry, University of Washington, Seattle, WA, 98195-1700, USA
SO Journal of the American Chemical Society (2003), 125(47), 14236-14237
CODEN: JACSAT; ISSN: 0002-7863
PB American Chemical Society
DT Journal
LA English
AB The functions of six genes in the ansamitocin biosynthetic gene cluster of Actinosynnema pretiosum have been investigated by gene inactivation and chemical anal. of the mutants. They encode a halogenase (asm12), a carbamoyltransferase (asm21), a 20-O-methyltransferase (asm7), a 3-O-acyltransferase (asm19), an epoxidase (asm11), and an N-methyltransferase (asm10), resp., and are responsible for the six post-PKS modification steps in ansamitocin formation. Several of the enzymes have relaxed substrate specificities, resulting in multiple parallel pathways in a metabolic grid, albeit with a preferred sequence of reactions as listed above.
IT 72902-38-6 637777-94-7 637777-97-0
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(gene inactivation anal. addresses post-polyketide synthase steps in ansamitocin biosynthetic gene cluster of Actinosynnema pretiosum)
RN 72902-38-6 CAPLUS
CN Maytansine, 2'-de(acetylmethylamino)-O20-demethyl-2'-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 637777-94-7 CAPLUS
CN Maytansine, 2'-de(acetylmethylamino)-20-O-demethyl-2'-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 637777-97-0 CAPLUS
CN Propanoic acid, 2-methyl-, (7R,8S,12S,13S,16R)-8,22-dihydroxy-7-methoxy-3,13,15-trimethyl-10,18-dioxo-11-oxa-9,19-diazatricyclo[18.3.1.18,12]pentacosa-1(24),3,5,14,20,22-hexaen-16-yl ester (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



OSC.G 18 THERE ARE 18 CAPLUS RECORDS THAT CITE THIS RECORD (18 CITINGS)
RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1993:573688 CAPLUS Full-text
DN 119:173688
OREF 119:30807a,30810a
TI A fluorescent probe and a photoaffinity labeling reagent to study the binding site of maytansine and rhizoxin on tubulin
AU Sawada, Takayuki; Kato, Yuzo; Kobayashi, Hisayoshi; Hashimoto, Yuichi; Watanabe, Tohru; Sugiyama, Yuichi; Iwasaki, Shigeo
CS Inst. Mol. Cell. Biosci., Univ. Tokyo, Tokyo, 113, Japan
SO Bioconjugate Chemistry (1993), 4(4), 284-9
CODEN: BCCHES; ISSN: 1043-1802
DT Journal
LA English
AB A fluorescent probe (20-demethoxy-20-[3-[[[5-(dimethylamino)naphthalen-1-yl]sulfonyl]amino]propyl]maytansinol 3-isobutyrate, Dan-PDM-3) and a photoaffinity labeling reagent (20-demethoxy-20-[(p-azidobenzoyl)oxy]maytansinol 3-isobutyrate, DABMI) were prepared by derivatization of ansamitocin P-3 (ASMP-3), a maytansinoid. Dan-PDM-3-consists of a tethered dansyl moiety and a maytansinoid moiety. DABMI contains a p-azidobenzoyl group instead of the tethered dansyl moiety of Dan-PDM-3. These compds. were synthesized by reacting 20-demethoxy-20-hydroxymaytansinol-3 isobutyrate (PDM-3) with the corresponding alkyl halide or benzoic acid. Both inhibit tubulin polymerization as potently as ASMP-3 and compete with ASMP-3 for binding to tubulin. The inhibition consts. (Ki) of DABMI for the binding to tubulin of rhizoxin and ASMP-3 were 0.54 and 0.36 μM, resp., which were nearly equal to the dissociation constant (Kd = 0.43 μM) of DABMI measured by the use of [14C]DABMI. The results suggest that Dan-PDM-3 and DABMI interacted with tubulin at the same site as rhizoxin and maytansine. DABMI is irreversibly bound to tubulin upon irradiation Dan-PDM-3 and DABMI should be useful probes for studying the binding site.
IT 72902-38-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactions of, with alkyl halide or benzoic acid)
RN 72902-38-6 CAPLUS
CN Maytansine, 2'-de(acetylmethylamino)-O20-demethyl-2'-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



OSC.G 14 THERE ARE 14 CAPLUS RECORDS THAT CITE THIS RECORD (14 CITINGS)

L19 ANSWER 7 OF 18 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1990:216514 CAPLUS Full-text
DN 112:216514
OREF 112:36537a,36540a
TI Studies on structure-activity relationships of mitotic poisons and their binding sites on tubulin
AU Kato, Yuzo; Ogawa, Yuji; Takahashi, Masaaki; Kobayashi, Hisayoshi; Iwasaki, Shigeo; Sugiyama, Yuichi
CS Inst. Appl. Microbiol., Univ. Tokyo, Tokyo, Japan
SO Tennen Yuki Kagobutsu Toronkai Koen Yoshishu (1989), 31st, 236-43
CODEN: TYKYDS
DT Journal
LA Japanese
AB A report from a symposium describing the synthesis of derivs. of rhizoxin and 20-demethoxy-20-hydroxyansamitocin P-3 and their tubulin polymerization inhibitor activity. The structure activity relationships and their binding sites on tubulin were also discussed.
IT 72902-38-6DP, derivs.
RL: PREP (Preparation)
(preparation and tubulin polymerization inhibitor activity of)
RN 72902-38-6 CAPLUS
CN Maytansine, 2'-de(acetylmethylamino)-O20-demethyl-2'-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L19 ANSWER 8 OF 18 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1984:121094 CAPLUS Full-text
DN 100:121094
OREF 100:18433a,18436a
TI Maytansinoid compounds
PA Takeda Chemical Industries, Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 10 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 58167592	A	19831003	JP 1982-49836	19820326
	JP 01052397	B	19891108		
PRAI	JP 1982-49836		19820326		

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Twenty-three maytansinoid compds. I [R = alkyl; X = Q, Q1, Q2, Q3 (R1, R2 = H, alkyl; R1R2 may be CH2)] were prepared by oxidation of II optionally followed by reduction and alkylation. I had mitosis inhibitory, anticarcinogenic, antifungal, and anti-protozoa activities (no data). Thus, treatment of 1.24 g II (R = Me2CH) in MeOH containing KH2PO4 with 250 mL Flemy's salt-saturated H2O for 3 h followed by SiO2 gel thin layer chromatog. of the product (22 mg) gave 18 mg I (R = Me2CH, X = Q) and I (R = Me2CH, X = Q1).

IT 89153-74-2P 89153-75-3P 89153-76-4P
89153-77-5P 89153-78-6P 89153-79-7P
89153-80-0P 89153-81-1P 89153-82-2P
89153-83-3P 89153-88-8P 89153-89-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 89153-74-2 CAPLUS
CN Maytansine, 2'-de(acetylmethylamino)-20-O-demethyl-21-hydroxy-2'-methyl- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 89153-75-3 CAPLUS
CN Maytansine, 3-O-de[2-(acetylmethylamino)-1-oxopropyl]-20-O-demethyl-21-hydroxy-3-O-(3-methyl-1-oxobutyl)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 89153-76-4 CAPLUS
CN Maytansine, 2'-de(acetylmethylamino)-21-hydroxy-2'-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 89153-77-5 CAPLUS
CN Maytansine, 2'-de(acetylmethylamino)-20-O-demethyl-21-methoxy-2'-methyl- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 89153-78-6 CAPLUS
CN Maytansine, 2'-de(acetylmethylamino)-21-hydroxy-2'-methyl-31-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 89153-79-7 CAPLUS
CN Maytansine, 2'-de(acetylmethylamino)-20-O-demethyl-2'-methyl-21-(phenylmethoxy)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 89153-80-0 CAPLUS
CN Maytansine, 3-O-de[2-(acetylmethylamino)-1-oxopropyl]-20-O-demethyl-21-hydroxy-3-O-(3-methyl-1-oxobutyl)-20-O-(2-oxo-2-phenylethyl)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 89153-81-1 CAPLUS
CN Maytansine, 3-O-de[2-(acetylmethylamino)-1-oxopropyl]-20-O-demethyl-3-O-(3-methyl-1-oxobutyl)-21-(2-oxo-2-phenylethoxy)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 89153-82-2 CAPLUS
CN Maytansine, 3-O-de[2-(acetylmethylamino)-1-oxopropyl]-21-hydroxy-3-O-(3-methyl-1-oxobutyl)-31-(methylthio)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 89153-83-3 CAPLUS
CN Maytansine, 3-O-de[2-(acetylmethylamino)-1-oxopropyl]-20-O-demethyl-3-O-(3-methyl-1-oxobutyl)-21-[(methylthio)methoxy]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 89153-88-8 CAPLUS
CN Maytansine, 2'-de(acetylmethylamino)-20-O-demethyl-17-hydroxy- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 89153-89-9 CAPLUS
CN Maytansine, 2'-de(acetylmethylamino)-20-O-demethyl-17-hydroxy-2'-methyl- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



IT 72902-38-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, maytansinoid from)
RN 72902-38-6 CAPLUS
CN Maytansine, 2'-de(acetylmethylamino)-O20-demethyl-2'-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L19 ANSWER 9 OF 18 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1983:214129 CAPLUS Full-text
DN 98:214129
OREF 98:32539a,32542a
TI Fermentative preparation of demethylmaytansinoids
IN Asai, Mitsuko; Nakahama, Kazuo; Izawa, Motowo
PA Takeda Chemical Industries, Ltd. , Japan
SO U.S., 32 pp. Division of U.S. 4,307,016.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4361650	A	19821130	US 1981-290943	19810807
	JP 54128598	A	19791005	JP 1978-34645	19780324
	JP 55085592	A	19800627	JP 1978-160787	19781222
	JP 62013958	B	19870330		
	ZA 7901350	A	19800430	ZA 1979-1350	19790321
	JP 62013959	B	19870330	JP 1979-119959	19790917
	JP 55118490	A	19800911		
	US 4307016	A	19811222	US 1980-153522	19800527
PRAI	JP 1978-34645	A	19780324		
	JP 1978-160787	A	19781222		
	US 1979-19612	A2	19790312		
	KR 1979-2968	U	19790830		
	JP 1979-119959	A	19790917		
	US 1980-153522	A3	19800527		
	GR 1979-58533	A	19790307		

AB Novel demethylmaytansinoids (I; X = Cl or H; R = H or acyl) are produced from maytansinoids by microbial transformation. Thus, Bacillus megaterium (FO 12108 was inoculated into a pH 7.5 medium containing dextrin 2, peptone 0.5, yeast extract 0.5, and meat extract 0.5% and shake-cultured at 30° for 16 h. To 2.75 L of this culture, 110 mg ansamitocin P-4 was added and cultivation was continued for 51 h. At this time, I had disappeared and PDM-4 had appeared in the medium. The demethylmaytansinoids have fungicidal, protozoacidal, and antitumor activities.

IT 72902-34-2P 72902-36-4P 72902-38-6P
72902-42-2P 72902-46-6P 72902-47-7P
72902-48-8P 72902-49-9P 72902-50-2P
72902-51-3P 72902-52-4P 72902-53-5P
72902-67-1P 72902-68-2P 72902-69-3P
72911-47-8P 72925-67-8P 72937-57-6P
72937-58-7P 72938-06-8P 76959-54-1P
RL: BMF (Bioindustrial manufacture); BIOL (Biological study); PREP (Preparation)
(manufacture of, by microbial demethylation)

RN 72902-34-2 CAPLUS
CN Maytansine, 3-de[2-(acetylmethylamino)-1-oxopropoxy]-O20-demethyl-3-(3-methyl-1-oxobutoxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 72902-36-4 CAPLUS
CN Maytansine, 2'-de(acetylmethylamino)-O20-demethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 72902-38-6 CAPLUS
CN Maytansine, 2'-de(acetylmethylamino)-O20-demethyl-2'-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 72902-42-2 CAPLUS
CN Maytansine, 3-de[2-(acetylmethylamino)-1-oxopropoxy]-O20-demethyl-3-[(1-oxohexyl)oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 72902-46-6 CAPLUS
CN Maytansine, 2'-de(acetylmethylamino)-19-dechloro-O20-demethyl-2'-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 72902-47-7 CAPLUS
CN Maytansine, O20-demethyl- (9CI) (CA INDEX NAME)



RN 72902-48-8 CAPLUS
CN Maytansine, N2'-deacetyl-O20-demethyl-N2'-(2-methyl-1-oxopropyl)- (9CI) (CA INDEX NAME)





RN 72902-49-9 CAPLUS
CN Maytansine, N2'-deacetyl-O20-demethyl-N2'-(3-methyl-1-oxobutyl)-, (2'R)- (9CI) (CA INDEX NAME)





RN 72902-50-2 CAPLUS
CN Maytansine, 3-de[2-(acetylmethylamino)-1-oxopropoxy]-O20-demethyl-3-[(1-oxopentyl)oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 72902-51-3 CAPLUS
CN Maytansine, 3-de[2-(acetylmethylamino)-1-oxopropoxy]-O20-demethyl-3-[(1-oxoheptyl)oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 72902-52-4 CAPLUS
CN Maytansine, 3-de[2-(acetylmethylamino)-1-oxopropoxy]-O20-demethyl-3-[(1-oxooctyl)oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 72902-53-5 CAPLUS
CN Maytansine, 2'-de(acetylmethylamino)-O20-demethyl-3'-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 72902-67-1 CAPLUS
CN Maytansine, N2',O20-didemethyl-N2'-(phenylmethyl)- (9CI) (CA INDEX NAME)





RN 72902-68-2 CAPLUS
CN Maytansine, O20-demethyl-3'-phenyl- (9CI) (CA INDEX NAME)





RN 72902-69-3 CAPLUS
CN Maytansine, 3-O-de[2-(acetylmethylamino)-1-oxopropyl]-20-O-demethyl-3-O-(1-oxobutyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 72911-47-8 CAPLUS
CN Maytansine, N2'-deacetyl-O20-demethyl-N2'-(1-oxopropyl)- (9CI) (CA INDEX NAME)



RN 72925-67-8 CAPLUS
CN Maytansine, 3-[[2-(acetylmethylamino)-4-methyl-1-oxopentyl]oxy]-3-de[2-(acetylmethylamino)-1-oxopropoxy]-O20-demethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 72937-57-6 CAPLUS
CN Maytansine, O20-demethyl-, (2'R)- (9CI) (CA INDEX NAME)



RN 72937-58-7 CAPLUS
CN Maytansine, N2'-deacetyl-O20-demethyl-N2'-(2-methyl-1-oxopropyl)-, (2'R)-
(9CI) (CA INDEX NAME)





RN 72938-06-8 CAPLUS
CN Maytansine, N2'-deacetyl-O20-demethyl-N2'-(1-oxopropyl)-, (2'R)- (9CI) (CA INDEX NAME)





RN 76959-54-1 CAPLUS
CN Maytansine, 19-dechloro-O20-demethyl-, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



OSC.G 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 10 OF 18 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1983:143193 CAPLUS Full-text
DN 98:143193
OREF 98:21805a,21808a
TI 9-Thiomaytansinoids and their use
IN Hashimoto, Naoto; Shimadzu, Hiroshi
PA Takeda Chemical Industries, Ltd. , Japan
SO Eur. Pat. Appl., 21 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 65730	A1	19821201	EP 1982-104284	19820515
	EP 65730	B1	19860910		
	R: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
	JP 57192389	A	19821126	JP 1981-76993	19810520
	JP 01014918	B	19890314		
	US 4424219	A	19840103	US 1982-374158	19820503
	AT 22082	T	19860915	AT 1982-104284	19820515
	CA 1169423	A1	19840619	CA 1982-403181	19820518
PRAI	JP 1981-76993	A	19810520		
	EP 1982-104284	A	19820515		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS MARPAT 98:143193
GI



I

AB 9-Thiomaytansinoids I (R = H, acyl; R1 = H, Cl; R2 = H, alkylsulfonyl, alkyl, aralkyl) were prepared Thus 685 mg ansamitocin P-3 was treated with 246 mg P2S5 to give 387 mg 9-thioansamitocin P-3 which at 200 μg/kg i.p. increased the lifespan of leukemia P-388-infected mice by 171%.
IT 72902-38-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(thiolation of)
RN 72902-38-6 CAPLUS
CN Maytansine, 2'-de(acetylmethylamino)-O20-demethyl-2'-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



OSC.G 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

L19 ANSWER 11 OF 18 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1982:562706 CAPLUS Full-text
DN 97:162706
OREF 97:27133a,27136a
TI 4,5-Deoxymaytansinoids and their use
IN Akimoto, Hiroshi; Kawai, Akiyoshi
PA Takeda Chemical Industries, Ltd. , Japan
SO Eur. Pat. Appl., 31 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 49528	A1	19820414	EP 1981-108030	19811007
R: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
WO 8201188	A1	19820415	WO 1980-JP240	19801008
W: MC				
US 4371533	A	19830201	US 1981-306776	19810929
JP 57098286	A	19820618	JP 1981-156363	19810930
JP 01048912	B	19891020		
CA 1160629	A1	19840117	CA 1981-387161	19811002
PRAI WO 1980-JP240	A	19801008		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS MARPAT 97:162706
GI



I

AB Deoxymaytansinoids I (R = H, acyl; R1 = H, Cl; R2 = H, alkyl, acyl, sulfonyl, carbamoyl) were prepared Thus maytansinol was treated with TiCl3 and LiAlH4 to give 4,5-deoxymaytansinol which was esterified with Me2CHCO2H to give 4,5-deoxyansamitocin P-3 (II). At 50 μg/kg i.p. II increased the survival time of melanoma B-16 infected mice to 240%.

IT 82551-40-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and esterification of)

RN 82551-40-4 CAPLUS
CN Maytansine, 2'-de(acetylmethylamino)-4,5-deepoxy-4,5-didehydro-20-O-demethyl-2'-methyl-, (4E)- (CA INDEX NAME)


O
O
C
Pr-i
O
O
NH
OH
OMe
Me
Me
O
N
Me
Cl
Me
OH

L19 ANSWER 12 OF 18 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1982:160697 CAPLUS Full-text
DN 96:160697
OREF 96:26443a,26446a
TI Demethylation of ansamitocins and related compounds
AU Izawa, Motowo; Nakahama, Kazuo; Kasahara, Fumiko; Asai, Mitsuko; Kishi, Toyokazu
CS Cent. Res. Div., Takeda Chem. Ind., Ltd., Osaka, 532, Japan
SO Journal of Antibiotics (1981), 34(12), 1587-90
CODEN: JANTAJ; ISSN: 0021-8820
DT Journal
LA English
GI



I, R1=H
II, R1=Me

AB The 20-demethyl derivs. (I) of ansamitocins (II) are produced by incubation of the corresponding methylated compound with Bacillus megaterium. The compds. produced in this way include the following: PDM-4 (I, R = COCH2CHMe2), PDM-3 (I, R = COCHMe2), PDM-2 (I, R = COCH2Me), PDM-1 (I, R = COMe), and PDM-0 (I, R = H).

IT 72902-36-4P
RL: PREP (Preparation)
(preparation of, from ansamitocin P-2 with Bacillus megaterium)
RN 72902-36-4 CAPLUS
CN Maytansine, 2'-de(acetylmethylamino)-O20-demethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



IT 72902-38-6P
RL: PREP (Preparation)
(preparation of, from ansamitocin P-3 with Bacillus megaterium)
RN 72902-38-6 CAPLUS
CN Maytansine, 2'-de(acetylmethylamino)-O20-demethyl-2'-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



IT 72902-34-2P
RL: PREP (Preparation)
(preparation of, from ansamitocin P-4 with Bacillus megaterium)
RN 72902-34-2 CAPLUS
CN Maytansine, 3-de[2-(acetylmethylamino)-1-oxopropoxy]-O20-demethyl-3-(3-methyl-1-oxobutoxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



OSC.G 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)

L19 ANSWER 13 OF 18 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1982:100646 CAPLUS Full-text
DN 96:100646
OREF 96:16481a,16484a
TI Microbial conversion of ansamitocin
AU Nakahama, Kazuo; Izawa, Motowo; Asai, Mitsuko; Kida, Makoto; Kishi, Toyokazu
CS Cent. Res. Div., Takeda Chem. Ind., Ltd., Osaka, 532, Japan
SO Journal of Antibiotics (1981), 34(12), 1581-6
CODEN: JANTAJ; ISSN: 0021-8820
DT Journal
LA English
OS CASREACT 96:100646
AB Bacteria, actinomycetes, yeasts, and fungi were screened for their ability to modify the structure of ansamitocins, a group of antitumor ansamycin antibiotics. Many strains, mostly actinomycetes, converted ansamitocin P-3 to ≥1 product. These products, compds. A, B, C, and D, were prepared with Bacillus megaterium IFO 12108, Streptomyces coelicolor IFO 3807, Streptomyces castaneus IFO 13670, and Streptomyces minutiscleroticus IFO 13361, and were identified as 20-O-demethylansamitocin P-3, maytansinol, 15-hydroxyansamitocin P-3, and N-demethylansamitocin P-3, resp. Other maytansinoids also underwent these microbial conversions.
IT 72902-38-6
RL: FORM (Formation, nonpreparative)
(formation of, from ansamitocin antibiotic by microorganisms)
RN 72902-38-6 CAPLUS
CN Maytansine, 2'-de(acetylmethylamino)-O20-demethyl-2'-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



OSC.G 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)

L19 ANSWER 14 OF 18 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1981:532912 CAPLUS Full-text
DN 95:132912
OREF 95:22263a,22266a
TI Maytansinoid compounds
PA Takeda Chemical Industries, Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 10 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 56020592	A	19810226	JP 1979-97779	19790730
	US 4309428	A	19820105	US 1980-171459	19800723
	EP 25496	A1	19810325	EP 1980-104413	19800726
	R: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
	CA 1147680	A1	19830607	CA 1980-357234	19800729
PRAI	JP 1979-97779	A	19790730		
	JP 1980-78142	A	19800609		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
GI



I

AB Eighteen maytansinoid compds. I [R = (un)substituted alkyl; R1 = H, Cl] (II) were prepared by alkylation of I (R = H). II had anticarcinogenic, antifungal, antiprotozoa, and antibacterial activities (5-100 μg/kg). Thus, a mixture of 31 mg I (R = H, R1 = Cl), 50 μL N NaOH, 16 mg cetyltrimethylammonium chloride, and 15 mg 4-MeC6H4SO3Et in aqueous CH2Cl2 was stirred 20 h at room temperature to give 4.8 mg II (R = Et, R1 = Cl).

IT 72902-38-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(etherification of)

RN 72902-38-6 CAPLUS
CN Maytansine, 2'-de(acetylmethylamino)-O20-demethyl-2'-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L19 ANSWER 15 OF 18 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1981:515624 CAPLUS Full-text
DN 95:115624
OREF 95:19413a,19416a
TI Maytansinoids and their use
IN Miyashita, Osamu; Hiroshi, Akimoto
PA Takeda Chemical Industries, Ltd., Japan
SO Eur. Pat. Appl., 32 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 25496	A1	19810325	EP 1980-104413	19800726
	R: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
	JP 56020592	A	19810226	JP 1979-97779	19790730
	JP 57004993	A	19820111	JP 1980-78142	19800609
	JP 01014237	B	19890310		
PRAI	JP 1979-97779	A	19790730		
	JP 1980-78142	A	19800609		

OS MARPAT 95:115624
GI



I

AB Maytansinoid ethers I (R = H, Cl; R1 = optionally substituted alkyl; R2 = alkyl) were prepared Thus ansamytocin P-3 was fermentatively demethylated to give I (R = Cl, R1 = H, R2 = CHMe2), which was etherified with PhCH2Br to give I (R = Cl, R1 = CH2Ph, R2 = CHMe2; II). II had a min. inhibitory concentration against Tetrahymena pyriformis W of <1 μg/mL and at 25 μg/kg day i.p. for 9 days increased the survival time of melanoma B-16-infected mice by 182%.

IT 72902-38-6P 72902-46-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and etherification of)
RN 72902-38-6 CAPLUS
CN Maytansine, 2'-de(acetylmethylamino)-O20-demethyl-2'-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 72902-46-6 CAPLUS
CN Maytansine, 2'-de(acetylmethylamino)-19-dechloro-O20-demethyl-2'-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L19 ANSWER 16 OF 18 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1981:497867 CAPLUS Full-text
DN 95:97867
OREF 95:16451a,16454a
TI Maytansinoids and their use
IN Miyashita, Osamu; Akimoto, Hiroshi
PA Takeda Chemical Industries, Ltd., Japan
SO Eur. Pat. Appl., 20 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 25108	A1	19810318	EP 1980-104462	19800729
	EP 25108	B1	19830209		
	R: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
	JP 56022790	A	19810303	JP 1979-98010	19790731
	AT 2432	T	19830315	AT 1980-104462	19800729
	CA 1148489	A1	19830621	CA 1980-357361	19800730
PRAI	JP 1979-98010	A	19790731		
	EP 1980-104462	A	19800729		

OS MARPAT 95:97867
GI



I

AB Maytansinoid sulfonates I (R = SO2R3; R1 = alkyl; R2 = H, Cl; R3 = alkyl, aralkyl, optionally substituted Ph) were prepared Thus ansamitocin P-3 was demethylated fermentatively to I (R = H, R1 = CHMe2, R2 = Cl) which was treated with MeSO2Cl to give I (R = SO2Me, R1 = CHMe2, R2 = Cl). At 6.2 μg/kg day i.p. for 9 days the latter compound increased the survival time of melanoma B-16-infected mice to 154%. I (R = SO2C6H4R4-4, R1 = CHMe2, R2 = Cl, R4 = Me, Cl, NH2) had min. inhibitory concns. of 1-4 μg/mL against Tetrahymena pyriformis W.

IT 72902-38-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and sulfonylation of)

RN 72902-38-6 CAPLUS
CN Maytansine, 2'-de(acetylmethylamino)-O20-demethyl-2'-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



IT 72902-46-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 72902-46-6 CAPLUS
CN Maytansine, 2'-de(acetylmethylamino)-19-dechloro-O20-demethyl-2'-methyl-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L19 ANSWER 17 OF 18 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1981:443191 CAPLUS Full-text
DN 95:43191
OREF 95:7397a,7400a
TI 20-O-Acylmaytansinoids, and pharmaceutical compositions containing them
IN Asai, Mitsuko; Izawa, Motowo; Nakahama, Kazuo
PA Takeda Chemical Industries, Ltd., Japan
SO Eur. Pat. Appl., 126 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 14402	A1	19800820	EP 1980-100412	19800128
EP 14402	B1	19830720		
R: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
JP 55102583	A	19800805	JP 1979-10551	19790131
US 4294757	A	19811013	US 1980-112237	19800115
CA 1131629	A1	19820914	CA 1980-344692	19800130
PRAI JP 1979-10551	A	19790131		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS MARPAT 95:43191
GI



I

AB Maytansinoids I (R = H, acyl; R1 = acyl; R2 = H, Cl) were prepared Thus I (R = COCHMe2, R1 = H, R2 = Cl) was acetylated to give I (R = COCHMe2, R1 = Ac, R2 = Cl). The starting materials were prepared from ansamitocin and some prepns. involved incubation with appropriate bacteria.
IT 72902-47-7 72937-57-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(hydride reduction of)
RN 72902-47-7 CAPLUS
CN Maytansine, O20-demethyl- (9CI) (CA INDEX NAME)



RN 72937-57-6 CAPLUS
CN Maytansine, O20-demethyl-, (2'R)- (9CI) (CA INDEX NAME)



IT 72902-47-7P 72937-57-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and acylation of)
RN 72902-47-7 CAPLUS
CN Maytansine, O20-demethyl- (9CI) (CA INDEX NAME)



RN 72937-57-6 CAPLUS
CN Maytansine, O20-demethyl-, (2'R)- (9CI) (CA INDEX NAME)



IT 72902-36-4P 72902-46-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and hydride reduction of)
RN 72902-36-4 CAPLUS
CN Maytansine, 2'-de(acetylmethylamino)-O20-demethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 72902-46-6 CAPLUS
CN Maytansine, 2'-de(acetylmethylamino)-19-dechloro-O20-demethyl-2'-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



IT 72902-34-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reduction of)
RN 72902-34-2 CAPLUS
CN Maytansine, 3-de[2-(acetylmethylamino)-1-oxopropoxy]-O20-demethyl-3-(3-methyl-1-oxobutoxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



IT 72902-38-6P 72902-42-2P 72902-48-8P
72902-49-9P 72902-50-2P 72902-51-3P
72902-52-4P 72902-53-5P 72902-67-1P
72902-68-2P 72911-47-8P 72925-67-0P
72937-58-7P 72938-06-8P 72938-07-9P
76959-54-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 72902-38-6 CAPLUS
CN Maytansine, 2'-de(acetylmethylamino)-O20-demethyl-2'-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 72902-42-2 CAPLUS
CN Maytansine, 3-de[2-(acetylmethylamino)-1-oxopropoxy]-O20-demethyl-3-[(1-oxohexyl)oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 72902-48-8 CAPLUS
CN Maytansine, N2'-deacetyl-O20-demethyl-N2'-(2-methyl-1-oxopropyl)- (9CI) (CA INDEX NAME)



RN 72902-49-9 CAPLUS
CN Maytansine, N2'-deacetyl-O20-demethyl-N2'-(3-methyl-1-oxobutyl)-, (2'R)- (9CI) (CA INDEX NAME)





RN 72902-50-2 CAPLUS
CN Maytansine, 3-de[2-(acetylmethylamino)-1-oxopropoxy]-O20-demethyl-3-[(1-oxopentyl)oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 72902-51-3 CAPLUS
CN Maytansine, 3-de[2-(acetylmethylamino)-1-oxopropoxy]-O20-demethyl-3-[(1-oxoheptyl)oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 72902-52-4 CAPLUS
CN Maytansine, 3-de[2-(acetylmethylamino)-1-oxopropoxy]-O20-demethyl-3-[(1-oxooctyl)oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 72902-53-5 CAPLUS
CN Maytansine, 2'-de(acetylmethylamino)-O20-demethyl-3'-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 72902-67-1 CAPLUS
CN Maytansine, N2',O20-didemethyl-N2'-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 72902-68-2 CAPLUS
CN Maytansine, O20-demethyl-3'-phenyl- (9CI) (CA INDEX NAME)





RN 72911-47-8 CAPLUS
CN Maytansine, N2'-deacetyl-O20-demethyl-N2'-(1-oxopropyl)- (9CI) (CA INDEX NAME)





RN 72925-67-8 CAPLUS
CN Maytansine, 3-[[2-(acetylmethylamino)-4-methyl-1-oxopentyl]oxy]-3-de[2-(acetylmethylamino)-1-oxopropoxy]-O20-demethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 72937-58-7 CAPLUS
CN Maytansine, N2'-deacetyl-O20-demethyl-N2'-(2-methyl-1-oxopropyl)-, (2'R)- (9CI) (CA INDEX NAME)



RN 72938-06-8 CAPLUS
CN Maytansine, N2'-deacetyl-O20-demethyl-N2'-(1-oxopropyl)-, (2'R)- (9CI) (CA INDEX NAME)



RN 72938-07-9 CAPLUS
CN Maytansine, N2'-deacetyl-O20-demethyl-N2'-(3-methyl-1-oxobutyl)- (9CI) (CA INDEX NAME)





RN 76959-54-1 CAPLUS
CN Maytansine, 19-dechloro-O20-demethyl-, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



OSC.G 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)

L19 ANSWER 18 OF 18 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1980:111076 CAPLUS Full-text
DN 92:111076
OREF 92:18137a,18140a
TI Demethyl maytansinoids and their uses
IN Mitsuko, Asai; Kazuo, Nakahama; Motowo, Izawa
PA Takeda Chemical Industries, Ltd., Japan
SO Eur. Pat. Appl., 129 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 4466	A1	19791003	EP 1979-300469	19790323
	EP 4466	B1	19820127		
	R: BE, CH, DE, FR, GB, IT, NL, SE				
	JP 54128598	A	19791005	JP 1978-34645	19780324
	JP 55085592	A	19800627	JP 1978-160787	19781222
	JP 62013958	B	19870330		
	AU 7945246	A	19790927	AU 1979-45246	19790319
	AU 519911	B2	19820107		
	CA 1144096	A1	19830405	CA 1979-323717	19790319
	ZA 7901350	A	19800430	ZA 1979-1350	19790321
	PL 124051	B1	19821231	PL 1979-214307	19790322
	DK 7901212	A	19790925	DK 1979-1212	19790323
	AT 7902191	A	19801115	AT 1979-2191	19790323
	AT 362872	B	19810625		
PRAI	JP 1978-34645		19780324		
	JP 1978-160787		19781222		

OS MARPAT 92:111076
GI



I

AB Demethylmaytansinoids I (R = H, acyl; R1 = H, Cl) were prepared Thus, 68 mg I (R = COCH2CHMe2, R1 = Cl, II) was obtained by demethylating 110 mg ansamitocin P-4 with Bacillus megaterium IFO 12108. II gave an inhibition zone of 24 mm against Hamigera avellanea in the paper disk method, impregnated with 0.2 mL of 100 μg/mL solution II had a protozoacidal min. inhibitory concentration against Tetrahymena pyriformis W of 1 μg/mL.

IT 72902-34-2P 72902-36-4P 72902-38-6P
72902-42-2P 72902-48-8P 72902-69-3P
72911-47-8P 72938-07-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and fungicidal and protozoacidal activity of)

RN 72902-34-2 CAPLUS
CN Maytansine, 3-de[2-(acetylmethylamino)-1-oxopropoxy]-O20-demethyl-3-(3-

methyl-1-oxobutoxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 72902-36-4 CAPLUS
CN Maytansine, 2'-de(acetylmethylamino)-O20-demethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 72902-38-6 CAPLUS
CN Maytansine, 2'-de(acetylmethylamino)-O20-demethyl-2'-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 72902-42-2 CAPLUS
CN Maytansine, 3-de[2-(acetylmethylamino)-1-oxopropoxy]-O20-demethyl-3-[(1-oxohexyl)oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 72902-48-8 CAPLUS
CN Maytansine, N2'-deacetyl-O20-demethyl-N2'-(2-methyl-1-oxopropyl)- (9CI) (CA INDEX NAME)





RN 72902-69-3 CAPLUS
CN Maytansine, 3-O-de[2-(acetylmethylamino)-1-oxopropyl]-20-O-demethyl-3-O-(1-oxobutyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 72911-47-8 CAPLUS
CN Maytansine, N2'-deacetyl-O20-demethyl-N2'-(1-oxopropyl)- (9CI) (CA INDEX NAME)



RN 72938-07-9 CAPLUS
CN Maytansine, N2'-deacetyl-O20-demethyl-N2'-(3-methyl-1-oxobutyl)- (9CI) (CA INDEX NAME)





IT 72902-49-9P 72902-50-2P 72902-51-3P
72902-52-4P 72902-53-5P 72902-67-1P
72902-68-2P 72925-67-8P 72937-58-7P
72937-59-8P 72938-06-8P 72938-08-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 72902-49-9 CAPLUS
CN Maytansine, N2'-deacetyl-O20-demethyl-N2'-(3-methyl-1-oxobutyl)-, (2'R)- (9CI) (CA INDEX NAME)





RN 72902-50-2 CAPLUS
CN Maytansine, 3-de[2-(acetylmethylamino)-1-oxopropoxy]-O20-demethyl-3-[(1-oxopentyl)oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 72902-51-3 CAPLUS
CN Maytansine, 3-de[2-(acetylmethylamino)-1-oxopropoxy]-O20-demethyl-3-[(1-oxoheptyl)oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 72902-52-4 CAPLUS
CN Maytansine, 3-de[2-(acetylmethylamino)-1-oxopropoxy]-O20-demethyl-3-[(1-oxooctyl)oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 72902-53-5 CAPLUS
CN Maytansine, 2'-de(acetylmethylamino)-O20-demethyl-3'-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 72902-67-1 CAPLUS
CN Maytansine, N2',O20-didemethyl-N2'-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 72902-68-2 CAPLUS
CN Maytansine, O20-demethyl-3'-phenyl- (9CI) (CA INDEX NAME)





RN 72925-67-8 CAPLUS
CN Maytansine, 3-[[2-(acetylmethylamino)-4-methyl-1-oxopentyl]oxy]-3-de[2-(acetylmethylamino)-1-oxopropoxy]-O20-demethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 72937-58-7 CAPLUS
CN Maytansine, N2'-deacetyl-O20-demethyl-N2'-(2-methyl-1-oxopropyl)-, (2'R)-(9CI) (CA INDEX NAME)





RN 72937-59-8 CAPLUS
CN Maytansine, N2',O20-didemethyl-N2'-(phenylmethyl)-, (2'R)- (9CI) (CA INDEX NAME)





RN 72938-06-8 CAPLUS
CN Maytansine, N2'-deacetyl-O20-demethyl-N2'-(1-oxopropyl)-, (2'R)- (9CI) (CA INDEX NAME)



RN 72938-08-0 CAPLUS
CN Maytansine, O20-demethyl-3'-phenyl-, (2'R)- (9CI) (CA INDEX NAME)



IT 72902-46-6P 72902-47-7P 72937-57-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation, hydrolysis, and fungicidal and protozoacidal activity of)
RN 72902-46-6 CAPLUS
CN Maytansine, 2'-de(acetylmethylamino)-19-dechloro-O20-demethyl-2'-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 72902-47-7 CAPLUS
CN Maytansine, O20-demethyl- (9CI) (CA INDEX NAME)





RN 72937-57-6 CAPLUS
CN Maytansine, O20-demethyl-, (2'R)- (9CI) (CA INDEX NAME)





=> d l2; d l6; d l11; d l16; d his; log y
L2 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.
L2 QUE ABB=ON PLU=ON L1

L6 HAS NO ANSWERS
L5 STR



Structure attributes must be viewed using STN Express query preparation.
L6 QUE ABB=ON PLU=ON L5

L11 HAS NO ANSWERS
L10 STR



Structure attributes must be viewed using STN Express query preparation.
L11 QUE ABB=ON PLU=ON L10

L16 HAS NO ANSWERS
L15 STR



Structure attributes must be viewed using STN Express query preparation.

```
L16             QUE  ABB=ON  PLU=ON  L15
     (FILE 'HOME' ENTERED AT 18:19:18 ON 15 DEC 2009)
     FILE 'REGISTRY' ENTERED AT 18:19:46 ON 15 DEC 2009
L1              STRUCTURE UPLOADED
L2              QUE L1
L3            0 S L2
L4            0 S L2 FUL
     FILE 'STNGUIDE' ENTERED AT 18:20:38 ON 15 DEC 2009
     FILE 'REGISTRY' ENTERED AT 18:29:06 ON 15 DEC 2009
L5              STRUCTURE UPLOADED
L6              QUE L5
L7            0 S L6
L8            4 S L6 FUL
     FILE 'CAPLUS' ENTERED AT 18:29:55 ON 15 DEC 2009
L9            2 S L8
     FILE 'REGISTRY' ENTERED AT 18:33:14 ON 15 DEC 2009
L10             STRUCTURE UPLOADED
L11             QUE L10
L12           0 S L11
L13           6 S L11 FUL
     FILE 'CAPLUS' ENTERED AT 18:33:45 ON 15 DEC 2009
     FILE 'REGISTRY' ENTERED AT 18:33:56 ON 15 DEC 2009
     FILE 'CAPLUS' ENTERED AT 18:34:00 ON 15 DEC 2009
L14           2 S L13
     FILE 'STNGUIDE' ENTERED AT 18:34:55 ON 15 DEC 2009
     FILE 'REGISTRY' ENTERED AT 18:36:32 ON 15 DEC 2009
L15             STRUCTURE UPLOADED
L16             QUE L15
L17           0 S L16
L18          43 S L16 FUL
     FILE 'CAPLUS' ENTERED AT 18:37:29 ON 15 DEC 2009
L19          18 S L18


COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                  ENTRY    SESSION
FULL ESTIMATED COST                              102.52     875.47

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)      SINCE FILE      TOTAL
                                                  ENTRY    SESSION
CA SUBSCRIBER PRICE                              -14.76     -18.04

STN INTERNATIONAL LOGOFF AT 18:38:45 ON 15 DEC 2009
```